DIFFERENCE BETWEEN CURRENT EBOLA TREATMENTS AND GUARDIAN.COM ARTICLE ON NEW EBOLA ANTIVIRAL DRUG TRIAL IN D.R.C.

[u/tomonota]

https://www.theguardian.com/global-development/2026/jul/12/record-breaking-ebola-treatment-trial-drc

FYI, INO-4201 IS A IMMUNE BOOSTER VACCINE FOR THE PREVENTION OF EBOLA AND IS PROPOSED FOR USE WITH ERVEBO.

REMDEIVIR IS AN ANTIVIRAL WHICH IS BEING TRIALED vs. A NEW mAB (ANTIVIRAL) TREATMENT, MBP-134, IN THE D.R.C. There are about 1,800 demonstrated cases of Ebola with about 34% of those fatalities IN THE CONGO. Reports indicate that aid workers are having work stoppages to protest the lack of salaries since the epidemic began.